Binding of Rab3 A to Synaptic Vesicles. by Chou, J. & Jahn, R.
Binding of Rab3A to Synaptic Vesicles*
(Received for publication, July 21, 1999, and in revised form, December 10, 1999)
Judy H. Chou‡§ and Reinhard Jahn‡¶i
From the ‡Howard Hughes Medical Institute and Departments of Cell Biology and Pharmacology, Yale University School
of Medicine, New Haven, Connecticut 06510 and the ¶Department of Neurobiology, Max Planck Institute for Biophysical
Chemistry, D-37077 Go¨ttingen, Germany
Prenylated Rab GTPases cycle between membrane-
bound and soluble forms. Membrane-bound GDP-Rabs
interact with GDP dissociation inhibitor (GDI), result-
ing in the dissociation of a RabzGDI complex, which in
turn serves as a precursor for the membrane re-associ-
ation of Rabs. We have now characterized the binding of
Rab3A to synaptic vesicles in vitro using either purified
complexes or rat brain cytosol as source for GDIzRab3A.
Binding of Rab3A results in the immediate release of
GDI from the membrane. Furthermore, binding does not
require the presence of additional guanine nucleotides
(GDP or GTP) or of cytosolic factors. Although nucleo-
tide exchange follows binding, binding is initially re-
versible, suggesting that binding of GDP-Rab3A and nu-
cleotide exchange are separate and independent events.
Comparison with the binding of Rab1B revealed that
both Rab proteins bind preferentially to their respective
resident membranes although some promiscuity was ob-
servable. Binding is saturable and involves a protease-
sensitive binding site that is tightly associated with the
vesicle membrane.
Rab proteins represent a Ras-related family of small GT-
Pases that are essential for intracellular membrane traffic.
Individual Rab proteins are specifically associated with mem-
braneous compartments and contribute to the selectivity of
vesicle targeting (for review see Refs. 1–4). Recent evidence
from both yeast and mammalian cells suggests that Rab pro-
teins are required for the initial contact formation of vesicles
destined to fuse (5, 6), probably via GTP-dependent interaction
with other proteins (7). Although Rab proteins appear not to be
part of the fusion reaction itself, they may be involved in the
control of soluble NSF attachment protein receptor proteins,
which mediate fusion. (8, 9).
Rab proteins cycle between the GTP- and GDP-bound forms.
Sets of specific proteins interact with GTP- and GDP-Rab pro-
teins, either shepherding them to the next step of the cycle or
executing a particular task in membrane traffic. The GTP
forms of Rabs are considered to represent the active conforma-
tions. GTP-Rab proteins bind to effector proteins. A number of
such effector proteins has been identified that structurally
belong to diverse protein families, and individual Rab proteins
may interact with multiple effectors (for review see Refs. 1 and
10). In addition, proteins are known that activate the GTPase
of specific Rabs (GTPase-activating proteins), that inhibit the
dissociation of GDP (GDP dissociation inhibitor, GDI),1 and
that mediate nucleotide exchange (guanine nucleotide ex-
change factors).
Most Rab proteins contain two hydrophobic geranylgeranyl
moieties at their C terminus that are responsible for membrane
anchoring. Despite these highly hydrophobic side chains, Rab
proteins undergo reversible membrane dissociation-association
cycles during membrane traffic that are correlated to their
GTP/GDP cycles. After GTP hydrolysis, membrane-bound
GDP-Rabs are recognized by GDP dissociation inhibitor
(RabzGDI) (11). RabzGDI forms a complex with GDP-Rabs that
shields their geranylgeranyl moieties and leads to their disso-
ciation from the membrane. GDIzRab complexes serve then as
the precursor form, which mediates the re-binding of Rab pro-
teins to their appropriate membrane (1, 2, 4). In addition to
RabzGDI, calmodulin has recently been suggested to remove
Rab3A from membranes in a calcium-dependent manner, but
the significance of this finding remains to be established (12).
In contrast to proteins mediating other parts of the Rab
cycle, the protein factors associated with the GDI-mediated
binding of Rab proteins to membranes are not well understood.
Since the various GDI isoforms appear to interact indiscrimi-
nately with all Rab proteins, membrane binding must be the
discerning step that is responsible for the specificity of mem-
brane binding. Consequently, the binding mechanism must be
able to recognize the specific type of Rab protein. In yeast, a
novel Golgi-associated membrane protein, termed Yip1p, has
recently been identified that appears to mediate the binding of
the Rab protein Ypt31p (13). Less is known about the binding
sites of mammalian Rabs. Membrane specificity has been dem-
onstrated for in vitro binding of several Rab proteins including
Rab4 and Rab5 (14, 15), which are localized to early endosomes,
and Rab 7 and Rab9 (16, 17), which are localized to late endo-
somes. These studies revealed that binding of Rab proteins
involves three distinct steps. First, the GDIzRab complex binds
to the membrane. Second, GDI dissociates after a delay of
several minutes. Recently, evidence for a protein factor has
been obtained that may be responsible for GDI-dissociation and
that appears to be specific for endosomal GDIzRab complexes
(18). Third, GTP is exchanged for GDP with the aid of guanine
nucleotide exchange factor proteins.
The present study was undertaken in order to investigate the
membrane-association of Rab3A. Rab3A is the predominant
Rab protein in the brain, which is exclusively localized to the
membrane of synaptic vesicles (19, 20) and which functions in
the regulation of neurotransmitter release (21, 22). Two addi-
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tional isoforms of Rab3A, Rab3B and Rab3C, respectively, are
also localized to synaptic vesicles (23, 24), whereas a fourth
isoform, Rab3D, is expressed in non-neuronal tissues (Ref. 25;
for review, see Refs. 10 and 26–28).
We have previously shown that the cycle of Rab3A is closely
linked to the recycling of synaptic vesicles. Before exocytosis,
vesicle-bound Rab3A is in the GTP form (29). Stimulation of
neurotransmitter release leads to GTP hydrolysis (29) and
causes a dissociation of Rab3A from the vesicle membrane that
is reversed during recovery from the stimulus (30). Here, we
show that the re-binding of Rab3A to synaptic vesicles can be
reconstituted in vitro. Binding involves the presence of a spe-
cific protein receptor that discriminates between Rab3A and
Rab1B, which was used for control. Furthermore, we found
that both Rab3A binding and dissociation of GDI occur inde-
pendently of guanine nucleotide exchange and that newly
bound Rab3A can be re-extracted with GDI as long as no
nucleotide exchange occurs.
EXPERIMENTAL PROCEDURES
Antibodies—GDI purified from bovine brain was used as antigen for
generating monoclonal antibodies in mice using standard procedures
(31, 32). A rabbit serum specific for Rab1B was raised using purified
Rab1B (see below) as antigen, employing standard procedures of the
Yale Animal Care Facility. The serum reacted with only a single band
in immunoblots of rat brain cytosol and did not cross-react with either
Rab3A or Rab5A (data not shown). The following monoclonal antibodies
were described previously and are now commercially available (Synap-
tic Systems): Rab3A (Cl 42.2; Ref. 33), Rab5 (Cl 621.1; Ref. 34), synap-
tophysin (C 7.2; Ref. 32), synaptotagmin (luminal domain, Cl 604.4),
and synaptobrevin (VAMP) 2 (Cl 69.1; Ref. 35). Rabbit sera against GDI
and sec 61 were generously provided by Dr. T. C. Su¨dhof (University of
Texas, Southwestern Medical Center, Dallas, TX) and Dr. T. Rapoport
(Harvard University, Boston, MA), respectively. The hybridoma line
producing antibodies for the myc epitope was obtained from American
Type Culture Collection. Rabbit anti-mouse Fc-specific antibodies were
obtained from Jackson ImmunoResearch. A monoclonal antibody spe-
cific for GaO2 was raised against recombinant protein and will be
described elsewhere.2
Generation of RabzGDI Complexes—GDI was purified from bovine
brain using ammonium sulfate precipitation and chromatography on
DEAE-Sephacel and Mono-Q, respectively. All steps were carried out as
described in Ref. 11, except that GDI was eluted from the Mono-Q
column by prolonged wash instead of a salt gradient.
Rab3A and Rab1B were expressed using the baculovirus system,
largely following the procedure described by others for Rab1 and Rab5
(36, 37). cDNAs for Rab3A and Rab1B were provided by Dr. P. De
Camilli (Yale University School of Medicine, New Haven, CT), and for
Rab5A by Dr. T. C. Su¨dhof. Full-length cDNAs encoding Rab3A, Rab5A,
and Rab1B were amplified by polymerase chain reaction from the
PET11d-Rab3A, PGEX-2T-Rab5A, and PALTER-Ex1-Rab1B con-
structs, respectively, using appropriate 59- and 39-oligonucleotide prim-
ers according to standard procedures. Unless indicated otherwise, the
59 primers were designed to add a myc epitope upstream of the respec-
tive 59 ends. The products were cloned into the BamHI site of the
baculovirus transfer vector pBlueBac His2 A, which contains an N-
terminal His6 tag. Constructs containing a single insert in the appro-
priate orientation were selected by restriction analysis and confirmed
by DNA sequencing. Construction and purification of recombinant vi-
ruses was performed using the MaxBac baculovirus system (Invitrogen)
according the manufacturer’s instructions. Sf9 cells were grown at
27 °C to a density of ;2 3 106 cells/ml in spinner flasks and infected
with recombinant viruses at a multiplicity of infection (virions/cell) of 5,
and incubation was continued for 72 h. The cells were harvested,
washed with phosphate-buffered saline, and resuspended in lysis buffer
(50 mM HEPES-KOH, pH 7.2, 1 mM MgCl2). Usually, the cells were
frozen in liquid N2 and stored at 280 °C at this stage.
To purify prenylated Rab proteins from Sf9 cells, a crude membrane
fraction was prepared. The cell suspension was supplemented with 0.3
M NaCl, 1 mM PMSF, 0.5 mg/ml leupeptin, and 1 mM pepstatin, sonicated
on ice four times each for 30 s with 30-s intervals at 50% intensity, and
centrifuged for 5 min at 900 3 g to remove cell debris and nuclei.
Membranes were then isolated from the supernatant by centrifugation
at 100,000 3 g for 1 h and washed once in the same buffer and once in
extraction buffer (20 mM Tris, pH 7.8, 150 mM NaCl) supplemented with
protease inhibitors as above. The pellet was then extracted in extrac-
tion buffer containing 1% (v/v) CHAPS and centrifuged at 100,000 3 g
for 30 min to remove non-soluble components.
The following steps involve formation of proteoliposomes, collection
of these liposomes by centrifugation, and subsequent re-extraction of
these liposomes by detergent. This procedure was shown previously to
greatly enrich membrane proteins with almost complete recovery, while
efficiently removing proteins without a membrane anchor such as non-
prenylated Rab proteins (38). To the resulting supernatant, 100 mg/ml
Biobeads SM2 were added in order to lower the detergent concentra-
tion. Following incubation on ice for a few minutes, the turbid extract
was removed from the beads and applied to 10 volumes of a Sephadex
G50 (fine) column for complete detergent removal. The turbid fractions
containing proteoliposomes were collected and centrifuged at 100,000 3
g for 30 min. The pellet was re-extracted in lysis buffer containing 1%
CHAPS. The extract was then used for purification on Ni21-nitrilotri-
acetic acid-agarose according to standard procedures. The final prod-
ucts contained no significant contaminations (as judged by SDS-PAGE);
they were stored at 230 °C in 50% glycerol until further use.
For the formation of RabzGDI complexes, equimolar amounts of Rab
protein and GDI (2 mM each) were mixed in the presence of 100 mM GDP
and 8 mM MgCl2, followed by extensive dialysis against a buffer con-
taining 64 mM HEPES-NaOH, pH 8.0, 100 mM NaCl, 8 mM MgCl2, 2 mM
EDTA, 0.2 mM dithiothreitol, 0.01 mM GDP, 0.1 mM phenylmethylsul-
fonyl fluoride, 0.5 mg/ml leupeptin, and 1 mM pepstatin. The mixture
was clarified by ultracentrifugation in a TLA 100.2 rotor at 95,000 rpm
for 10 min at 4 °C. The supernatant was collected as RabzGDI complex.
The complexes were kept on ice and normally used within 72 h.
Binding of Rab Proteins to Membranes—As acceptor membranes in
standard binding assays, a fraction enriched in synaptic vesicles (LP2
fraction) was prepared by first isolating synaptosomes from rat brain,
followed by hypotonic shock and differential centrifugation (39). When
indicated, synaptic vesicles were further purified from LP2 using, con-
secutively, sucrose density gradient centrifugation and chromatogra-
phy on controlled pore glass beads (CPG) (39, 40). The eluate from the
controlled pore glass bead column was divided in three fractions, one
enriched in large membranes (CPG I), one intermediate fraction (CPG
II), and one highly enriched in synaptic vesicles (CPG III; see Ref. 41 for
further details). Membranes enriched in endoplasmic reticulum (ER)
were obtained by consecutive differential and density gradient centrif-
ugation using Percoll and Nycodenz gradients (42). LP2 from Rab3A-
deficient mice was prepared as above. The mice (21) were kindly pro-
vided by Dr. T. C. Su¨dhof.
Binding or Rab proteins to membranes was measured as follows
unless indicated otherwise. The reaction mixture contained 10 mg of
membrane protein, 100 ng (4.5 nM) of RabzGDI complex, binding assay
buffer (25 mM HEPES-KOH, pH 7.2, 115 mM KCl, 1.5 mM Mg(OAc)2, 0.2
mM dithiothreitol, 100 mM (NH4)2SO4, 0.1 mM phenylmethylsulfonyl
fluoride, 0.5 mg/ml leupeptin, and 1 mM pepstatin), 100 mM guanine
nucleotide as indicated, and an ATP regeneration system (1.4 mM
MgCl2, 0.4 mM ATP, 6 mM phosphocreatine, 8 units of creatine phos-
phokinase), which, however, was omitted in later experiments. The
final assay volume was 250 ml. After incubation for 30 min at 37 °C the
reaction was stopped by addition of 500 ml of ice-cold assay buffer.
Membranes were sedimented by centrifugation in a TLA 100.2 rotor at
95,000 rpm for 10 min at 4 °C. The pellets were washed once with 500
ml of assay buffer and then analyzed by SDS-PAGE, followed by immu-
noblotting. In all experiments, the supernatants were also analyzed in
order to check whether unbound RabzGDI complex and/or released GDI
were recovered in the supernatants at the end of the binding reaction.
This was the case in all experiments described here. Under standard
conditions, about 40–50% of Rab3A remained in the supernatant with
an overall recovery (supernatant 1 pellet) of about 80%. Furthermore,
parallel incubations were carried out for each data point in which the
membranes were omitted, in order to rule out that Rab recovery in the
pellet fraction is due to aggregation. Each binding experiment shown
here was repeated independently at least three times, yielding very
similar results.
Guanine Nucleotide Exchange—Guanine nucleotide exchange was
monitored by the binding of radiolabeled GTPgS. In order to reduce
background binding of GTPgS to endogenous Rab proteins, the mem-
branes (200 mg of protein) were pre-incubated with 1 mM GDI in the
presence of 100 mM GDP using conditions identical to those in Rab
binding experiments. Incubations for nucleotide exchange were carried
out exactly as for Rab binding, except that 5 nM [35S]GTPgS (about 0.72 J. H. Chou and R. Jahn, manuscript in preparation.
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mCi/reaction) were present. The reactions were stopped by the addition
of 900 ml of ice-cold assay buffer. Protein-bound radioactivity was re-
covered by filtration through a Millipore HA type filter (0.45-mm pore
size) and quantitated by liquid scintillation counting.
Other Methods—SDS-PAGE was carried out according to Laemmli
(43). Immunoblotting on nitrocellulose membranes was performed ac-
cording to Ref. 44 using alkaline phosphatase enzymatic reaction
(Roche Molecular Biochemicals), 125I Protein A radiography (Amersham
Pharmacia Biotech), or enhanced chemiluminescence (Amersham Phar-
macia Biotech) detection. Protein concentrations were determined ac-
cording to Bradford (45) or with the BCA method (Pierce).
Protease treatment of membranes was carried out at a concentration
of 8 mg/ml membrane protein and 1 mg/ml trypsin (Roche Molecular
Biochemicals), bromelain (Sigma), and elastase (Roche Molecular Bio-
chemicals), respectively, for 1 h at 37 °C. The incubations were stopped
by 10-fold dilution with ice-cold incubation buffer (320 mM sucrose, 10
mM HEPES, pH 7.4) and the addition of 2 mg/ml appropriate protease
inhibitors (trypsin inhibitor (Roche Molecular Biochemicals), bromelain
inhibitor (Sigma), and elastatinal (Sigma)), respectively. Protease-
treated membranes were then isolated by ultracentrifugation
(100,000 3 g, 15 min, 4 °C) and tested for Rab binding activity using
standard assay conditions.
RESULTS
Generation and Characterization of GDIzRab Complexes—
GDI was purified from bovine brain (11). For the characteriza-
tion of GDI and RabzGDI complexes, we generated a panel of
mouse monoclonal antibodies specific for GDI. Clone Cl 81.2
showed the strongest reaction and was therefore used in all
subsequent experiments. When rat brain cytosol was analyzed
by SDS-PAGE and immunoblotting, a single band of an approx-
imate Mr 5 55,000 was detected by this antibody which comi-
grated with purified GDI (Fig. 1A). We then examined whether
the antibody was able to immunoprecipitate RabzGDI com-
plexes from cytosol. As shown in Fig. 1B, both GDI and Rab3A
were detectable in the immunoprecipitate. In contrast, the
a-subunit of the trimeric GTPase GO2 that is abundantly ex-
pressed on synaptic vesicles (46) did not co-precipitate, showing
the specificity of the immunoprecipitation procedure.
Posttranslationally modified Rab3A and Rab1B were pro-
duced in Sf9 cells using the baculovirus expression system. All
proteins contained an N-terminally attached His6 tag for affin-
ity purification. Furthermore, a myc epitope was added down-
stream of the His6 tag in order to differentiate the recombinant
Rab proteins from their endogenous counterparts. For Rab3A,
a version lacking the myc epitope was also prepared. When the
proteins were extracted and purified according to Ref. 36, the
resulting protein fractions were of low yield and purity, partic-
ularly for Rab3A and myc-Rab3A. Therefore, an additional
purification step was included. It involves the reconstitution of
all membrane proteins into proteoliposomes, separation of
these proteoliposomes from non-incorporated proteins, and re-
solubilization of the liposomes by detergent prior to affinity
chromatography. Yield and purity were significantly improved
(see “Experimental Procedures” for details). Rab3A purified by
this procedure bound stoichiometric amounts of GTP (data not
shown), demonstrating that its nucleotide binding pocket is
correctly folded.
RabzGDI complexes were formed by dialysis (see “Experi-
mental Procedures”). To examine whether GDI and Rab pro-
teins were indeed bound to each other after dialysis, GDI was
immunoprecipitated with monoclonal antibody Cl 81.2 and
then probed for the presence of the respective Rab protein. As
shown in Fig. 1C, virtually all of Rab3A coprecipitated with
GDI, indicating that no free Rab3A was present in the complex
fraction. Similar results were obtained for the other RabzGDI
complexes.
Basic Parameters of Rab3A Binding to Synaptic Vesicles—In
the first series of experiments, an assay for binding of Rab3A to
synaptic vesicles was established. A membrane fraction en-
riched about 5–8-fold in synaptic vesicles (LP2, see Refs. 32
and 39) was prepared from rat brain and used as acceptor in all
experiments unless indicated otherwise. After incubation of the
membranes with Rab3AzGDI complexes, bound Rab3A was
separated from unbound Rab3A by ultracentrifugation and
binding was measured by immunoblotting. LP2 contains endo-
genously bound Rab3A that needed to be differentiated from
the exogenously added variant. Therefore, the myc-tagged form
of Rab3A was used in most experiments, which is well sepa-
rated from endogenous Rab3A on SDS-polyacrylamide gels.
Unless indicated otherwise, both endogenous and exogenous
Rab3A were detected with a Rab3A-specific monoclonal anti-
body to allow for direct comparison. In order to control for
membrane recovery, synaptobrevin, an integral membrane
protein of synaptic vesicles, was monitored in parallel.
First, we defined the time dependence of the binding reac-
tion. The myc-Rab3AzGDI complex was incubated with synap-
tic vesicles under standard conditions (see “Experimental Pro-
FIG. 1. Monoclonal antibody Cl 81.2 specifically reacts with
GDI and immunoprecipitates RabzGDI complexes. A, immunoblot
of rat brain cytosol (approximately 6 mg) and purified GDI using mono-
clonal antibody Cl 81.2, detected with the alkaline phosphatase method.
B, coprecipitation of GDI and Rab3A from rat brain cytosol. For precip-
itation, 20 ml of ascites were mixed with 200 mg of cytosol protein in 320
mM sucrose, 100 mM NaCl, and 10 mM HEPES-KOH, pH 7.4, at a final
volume of 200 ml, followed by incubation at 4 °C for 1 h. Hundred ml of
protein G-Sepharose slurry was added, and the incubation was ex-
tended for 1 h. The beads were collected by centrifugation and washed
three times. Three percent of the precipitate was analyzed by SDS-
PAGE/immunoblotting using the enhanced luminescence method. For
detection, a polyclonal antiserum for GDI and monoclonal antibody Cl
42.2 for Rab3A were used. As control for nonspecific binding, the blot
was probed with a monoclonal antibody specific for the a-subunit of the
trimeric GTPase GO2, no cosedimentation was observed. C, coprecipi-
tation of GDI and Rab3A using purified Rab3AzGDI complexes in order
to determine the efficiency of complex formation. 1.5 mg of Rab3AzGDI
complex in phosphate-buffered saline (Coomassie Blue staining of the
electrophoretically separated complex is shown in the left panel) was
incubated with 20 ml of Cl 81.2 ascites in a final volume of 200 ml and
precipitated as above. After sedimentation of the Sepharose beads, both
the bead pellet and the first supernatant (containing unbound material)
were analyzed for GDI and Rab3A by SDS-PAGE and immunoblotting
using the alkaline phosphatase method for detection. Virtually all of
Rab3A coprecipitated with GDI, indicating that the purified complex
contains no unbound Rab3A.
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cedures”) for different time periods. Rab3 binding increased
from 0 to 30 min but did not increase further during prolonged
incubation (Fig. 2A). The amount of endogenous Rab3A on
synaptic vesicles did not change during the incubation. In
addition, no accumulation of GDI on the membrane was ob-
served at any time. Binding was dependent on the amount of
vesicles in an approximately linear manner between 5 and 50
mg of vesicle protein (data not shown), and 10 mg were used in
all subsequent experiments. Under standard conditions (10 mg
of vesicle protein, 30 min of incubation), about 35% of the
Rab3A added to the assay (as RabzGDI complex) was recovered
in the membrane pellet, with approximately 40% remaining
unbound (Fig. 2B). The loss of about 20–25% is probably due to
adsorption.
Next, we investigated whether the Rab3 pool found in the
membrane pellet after the binding reaction is indeed attached
to vesicles instead of representing aggregated proteins cosedi-
menting with the membranes. For this purpose, we used a
flotation gradient in order to separate the membranes from
unbound protein. The binding assay mix was adjusted to 38%
sucrose at the end of the reaction and overlaid with layers
consisting of 35% and 8% sucrose, respectively. After ultracen-
trifugation, the distribution of vesicles, GDI, and Rab3A on the
gradient was determined. As shown in Fig. 3, both GDI and
myc-Rab3A remained in the dense fraction when membranes
were omitted. In the presence of vesicles, however, the majority
of myc-Rab3A was found in fractions of lower density together
with the vesicles, as seen by the parallel distribution of synap-
tobrevin. GDI largely remained in the bottom of the gradient,
confirming that GDI does not bind to the vesicles.
Nucleotide Dependence of Rab3A Binding—Previous work on
the binding of Rab4, Rab5, and Rab9 to membranes demon-
strated that membrane binding is closely linked to nucleotide
exchange. We therefore tested whether binding of myc-Rab3A
to synaptic vesicles is influenced by the presence of GDP or the
non-hydrolyzable GTP analog GTPgS. As shown in Fig. 4A, no
change in the amount of bound myc-Rab3A was observed when
either of these nucleotides was present. We then investigated
whether nucleotide exchange does occur during the binding
reaction. This was indeed the case (Fig. 4B), but exchange
appeared to be slower than binding under our assay conditions
with no saturation reached after 60 min of incubation. Note
that, in this experiment, endogenous GDP-Rab proteins were
removed from the membrane by preincubation with free GDI.
This step was needed in order to reduce background binding of
GTPgS, which is known to be high (19).
These observations suggested that binding and guanine nu-
cleotide exchange are separate and independent events. Appar-
ently, GDI delivers Rab3A to the membrane and dissociates
during the binding reaction without the need for nucleotide
exchange, although, as shown above, nucleotide exchange does
occur if GTP (or GTP analogs) are present. Since free GDI is
capable of removing GDP-Rab proteins but not GTP-Rab pro-
teins from the membrane, these findings prompted us to inves-
tigate whether binding is reversible as long as no nucleotide
exchange occurs.
First, we tested whether addition of free GDI (in addition to
RabzGDI complexes) to the binding reaction would shift the
equilibrium toward unbound RabzGDI complexes. As shown in
Fig. 5, binding of myc-Rab3A was reduced in the presence of
excess free GDI. This effect was consistently seen in several
experiments.
The effects of free GDI are best explained by an equilibrium
between binding and dissociation in which GDP-Rab3 deliv-
ered by GDIzRab complexes is subsequently being removed by
free GDI. In order to examine this issue further, we performed
binding and GDI-mediated dissociation sequentially. We also
tested whether nucleotide exchange after binding of GDP-
FIG. 2. Binding of myc-Rab3A to synaptic vesicles under stand-
ard assay conditions. A, time dependence of Rab3A binding to syn-
aptic vesicles. The myc-Rab3AzGDI complex was incubated with synap-
tic vesicles (LP2) for different time periods using standard assay
conditions. The figure shows an immunoblot analysis of the bound
(pellet) fraction. Both myc-Rab3A and endogenous Rab3A were detected
with the Rab3A-specific monoclonal antibody Cl 42.2. In this and all
following experiments, the immunoblots were developed with the en-
hanced chemiluminescence method unless indicated otherwise. Binding
of myc-Rab3A increased from 0 to 30 min but did not increase further
upon extension of the incubation time. The amount of endogenous
Rab3A present in the vesicle fraction did not change during the course
of the incubation. B, recovery of GDI and Rab3A in the pellet (bound)
and supernatant (unbound) fractions. For comparison, all fractions are
normalized to the same relative volume. Note that both synaptobrevin
(a membrane marker) and endogenous Rab3A are recovered in the
pellet, whereas myc-Rab3A, derived from exogenously added myc-
Rab3AzGDI complex, was distributed between bound (approximately
35% of starting material) and unbound (approximately 40% of the
starting material). See “Experimental Procedures” for details.
FIG. 3. Bound myc-Rab3A comigrates with vesicle membranes
on a sucrose density flotation gradient. The binding reaction mix-
ture was brought to 38% sucrose in a final volume of 0.74 ml at the end
of a standard assay incubation and overlaid with 0.75 ml each of 35%
and 8% sucrose, respectively. After centrifugation at 50,000 rpm for
2.5 h in a Beckman SW 41 rotor, fractions were collected as indicated
and analyzed by immunoblotting. Top, standard assay; bottom, myc-
Rab3zGDI complex only.
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Rab3A would protect bound Rab3A from subsequent dissocia-
tion by GDI. In this experiment, binding was first carried out in
the presence of GDP under standard conditions and the mem-
branes were separated from unbound material by centrifuga-
tion. In a second step, these membranes were resuspended and
re-incubated with GDI in the presence of either GDP or GTPgS.
The result of this experiment is shown in Fig. 6A. When
vesicles containing bound myc-Rab3A were re-incubated with
GDI in the presence of GDP, myc-Rab3A was completely re-
moved from the membrane. Interestingly, the same result was
obtained when the first binding reaction was carried out in the
presence of GTP. When GTPgS was present instead of GDP,
part of the newly bound myc-Rab3A remained on the mem-
brane. Control incubations carried out in parallel showed that
this effect is due to GDI and not to the nucleotides alone, as no
removal was observed in the absence of GDI. For further con-
firmation, part of the experiment was repeated using rat brain
cytosol containing endogenous Rab3AzGDI complex instead of
purified Rab3AzGDI complex as Rab donor. To avoid interfer-
ence by vesicle-bound Rab3A, synaptic vesicles (LP2) were
prepared from transgenic mice, which lack a functional Rab3A
gene (KO-LP2) (21). The experiment depicted in Fig. 6B shows
that cytosol can be indeed used as Rab3 donor in the binding
experiment and confirms that binding is reversible as long as
no nucleotide exchange occurs. Furthermore, it shows that the
presence of cytosol (including soluble exchange factors such as
MSS4; Ref. 47) does not influence binding and its subsequent
reversal by GDI.
Characterization of the Rab3A Binding Site—In the follow-
ing experiments, we investigated whether exogenous Rab3A
only binds to synaptic vesicles and whether binding is depend-
ent on proteins in the target membrane. This issue is of impor-
tance as the re-binding reaction is supposed to be the discern-
ing step that is responsible for the highly selective association
of individual Rab proteins with their respective organelle.
In the first series of experiments, we compared the binding of
Rab3A with that of Rab1B. In contrast to the vesicle-specific
Rab3A, Rab1B functions in the transport of vesicles from the
ER to the Golgi and, at least under steady-state conditions, is
mostly associated with Golgi membranes (for review, see Ref.
4). GDI complexes of either myc-Rab3A or myc-Rab1B were
incubated in parallel with either brain-derived synaptic vesi-
cles (LP2) or with an ER fraction prepared from rat liver, i.e. a
tissue in which Rab3A is not expressed. Surprisingly, myc-
Rab3A bound to both ER and LP2 membranes, with only a
FIG. 4. Binding of Rab3A is accompanied by, but does not
depend on, guanine nucleotide exchange. A, Rab3A binding is
independent of the presence of guanine nucleotides. The myc-
Rab3AzGDI complex was incubated with synaptic vesicle membranes
without nucleotides (Buffer) or in the presence of 500 mM GTPgS or 500
mM GDP using standard assay conditions. B, Rab3A binding is accom-
panied by nucleotide exchange. The synaptic vesicle fraction used in the
assay was pre-treated with GDI in order to reduce background binding
(see text). Binding was performed in the presence of [35S]GTPgS. Bound
radioactivity was quantitated using a filtration assay (see “Experimen-
tal Procedures” for details).
FIG. 5. Addition of free GDI reduces binding of Rab3A. Binding
of myc-Rab3AzGDI to synaptic vesicles was performed under standard
assay conditions in the presence of 1 mM GDI, leading to a reduction of
both bound exogenous and bound endogenous Rab3A.
FIG. 6. Newly bound Rab3A is dissociated by GDI in the pres-
ence of GDP but becomes refractory after nucleotide exchange.
A, myc-Rab3AzGDI complex was first bound to synaptic vesicles (LP2)
using standard assay conditions. The membranes were then collected
by centrifugation, resuspended and re-incubated in the presence or
absence of 1 mM GDI and either 0.1 mM GTPgS or 0.1 mM GDP using
standard assay conditions. Note that GTPgS partially protects Rab3A
from re-dissociation by GDI. B, binding of Rab3A to synaptic vesicles is
reversed by GDI when rat brain cytosol is used as a source for
Rab3AzGDI complex. One hundred mg of rat brain cytosol was first
incubated with 10 mg of a synaptic vesicle fraction derived from Rab3A-
deficient mice (21) (KO-LP2, analyzed in the right lane to show that
endogenous Rab3A is absent) under standard conditions. The mem-
branes were then isolated and re-incubated as in A, except that disso-
ciation was only analyzed in the presence of GDP using rat brain cytosol
as source for Rab3AzGDI complex. Immunoblot analysis was performed
on half of the recovered membranes.
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slight preference for LP2 (Fig. 7, upper panel). Conversely,
myc-Rab1B bound equally well to both membranes despite the
fact that endogenous Rab1B, like the ER-resident protein sec
61, was enriched in the ER fraction in comparison to LP2.
Changing the binding conditions, for instance by substituting
GTPgS for GDP or by using Rab3AzGDI complex instead of
myc-Rab3AzGDI complex, did not change the result (data not
shown). For confirmation, we again used unfractionated rat
brain cytosol as source for the Rab3AzGDI complex and com-
pared binding to ER and an LP2 fraction derived from
Rab3A-KO mice. Again, there was preferential binding to LP2
but significant amounts of Rab3A became also associated with
the liver-derived ER fraction (Fig. 7, lower panel). Increasing
concentrations of cytosol increased the amount of bound Rab3A
but did not change the membrane preference (data not shown).
Although LP2 is enriched in synaptic vesicles, it still con-
tains significant membrane contaminants from other sources
including the ER (39). Vice versa, it is possible that the liver-
derived ER fraction is contaminated with small trafficking
vesicles that may contain a binding site interacting with
Rab3A, even though Rab3A is not expressed in liver. For these
reasons, we subfractionated LP2 further by continuous sucrose
density gradient centrifugation followed by chromatography on
CPG. CPG chromatography separates synaptic vesicles from
larger membranes, resulting in membrane fractions either
highly enriched (CPG III) or relatively de-enriched (CPG I),
respectively, in synaptic vesicles (39, 41) eluting from the same
column. When these fractions were analyzed for endogenous
Rab1B and Rab3A, an inverse distribution was found that
corresponded to that of the respective marker proteins synap-
tobrevin and sec 61 (Fig. 8). Binding of the corresponding
myc-Rab3A and myc-Rab1B, respectively, largely paralleled
the distribution of the endogenous proteins (Fig. 8). Together,
these results support the view that it is the membrane-rebind-
ing reaction which defines the specificity of the subcellular
localization of Rab proteins.
In order to confirm the independence of the binding sites for
Rab3A and Rab1B, we performed competition experiments.
Binding of myc-Rab3A was measured in the presence of in-
creasing concentrations of myc-Rab1B. Binding of myc-Rab3A
and myc-Rab1B were assayed using anti-myc tag monoclonal
antibodies, allowing for a direct comparison of the protein
quantities. As shown in Fig. 9A, increasing amounts of myc-
Rab1B failed to interfere with the binding of myc-Rab3A, with
only a slight reduction in the presence of a 10-fold excess of
Rab1BzGDI complex.
We next investigated whether Rab3-binding is saturable, a
feature suggested by the result of the competition experiments.
When increasing amounts of myc-Rab3AzGDI complex were
used in the binding reaction, saturation was observed at a
concentration of about 100 nM myc-Rab3AzGDI complex (Fig.
9B). The amount of endogenous Rab3A remained unchanged
over the entire concentration range, suggesting that saturation
is not caused by an increased dissociation rate under these
conditions.
Together, these results strongly suggest that Rab3 binding is
mediated by a protein receptor present in the vesicle mem-
brane. To address the nature of the receptor on synaptic vesicle
membranes, synaptic vesicles were treated with 1 M KCl or 0.1
M Na2CO3, pH 11, in order to strip off peripheral membrane
proteins. Binding of myc-Rab3A was not influenced by these
treatments (data not shown). We therefore used limited prote-
olysis of synaptic vesicles with three different proteases in
order to prove the proteinaceous nature of the receptor. Under
our experimental conditions, the cytoplasmic domains of syn-
aptic vesicle proteins were largely proteolyzed, shown here for
synaptotagmin (Fig. 10), where only the luminal domain was
detectable after digestion. Treatment with all three proteases
greatly reduced the binding of Rab3A to vesicle membranes,
FIG. 7. Comparison of Rab3A- and Rab1B-binding to mem-
branes enriched either in synaptic vesicles (LP2) or in ER. Top,
myc-Rab3AzGDI and myc-Rab1BzGDI complexes were incubated with
either LP2 or ER membranes under standard assay conditions. As
reference, the distribution of the respective endogenous proteins was
analyzed in parallel. Bottom, rat brain cytosol was used as a source for
Rab3AzGDI complexes. Cytosol was incubated either with LP2 derived
from Rab3A-KO mice (devoid of endogenous Rab3A, see Fig. 6) or with
ER membranes. All experiments were performed and analyzed using
standard conditions.
FIG. 8. Comparison of Rab3A and Rab1B binding with the
distribution of endogenous proteins using fractions obtained
during purification of synaptic vesicles by CPG chromatogra-
phy. CPG I contains mostly large membranes in addition to some
synaptic vesicles, whereas CPG III contains highly purified synaptic
vesicles with virtually no contamination by larger membranes (see
“Results” for details). All experiments were carried out under standard
conditions. Note that myc-Rab3A binds preferably to CPG III mem-
branes, in accordance with the distribution of the endogenous proteins.
The distributions of both endogenous Rab1B and myc-Rab1B-binding
are parallel to each other and are inversely related to that of Rab3B.
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with bromelain being most effective (Fig. 10, upper panel).
Reduction was not due to a diminished membrane recovery
since equal amounts of the luminal fragment of synaptotagmin
were recovered. Furthermore, no breakdown of unbound myc-
Rab3AzGDI complex was observed in the unbound fraction (Fig.
10, bottom), showing that the loss of binding is due to a loss of
a Rab3 receptor protein and not due to a digestion of
Rab3AzGDI complex by residual proteases.
DISCUSSION
In the present study, we have used several approaches to
study the binding of Rab3A to synaptic vesicles in vitro. Bind-
ing is a saturable, protein-mediated event that displays selec-
tivity for the appropriate target organelle. Furthermore, bind-
ing is independent of nucleotide exchange and is reversible as
long as no nucleotide exchange occurs. Our findings comple-
ment previous studies on the binding of endosomal Rab pro-
teins (14–17) and support the idea that the membrane recruit-
ment of Rab proteins proceeds in distinct steps involving
binding of the GDIzRab complex, dissociation of GDI, and nu-
cleotide exchange.
Several approaches were used to define whether the binding
reaction is specific for synaptic vesicles and thus reflects the
localization of endogenous proteins. For comparison, we tested
binding of Rab1B, which functions in the trafficking of vesicles
derived from the endoplasmic reticulum. Rab3A associates
preferentially with synaptic vesicles, whereas Rab1B preferen-
tially associates with larger membranes derived from the en-
doplasmic reticulum. However, specificity was not absolute
since some cross-binding was observed (particularly with re-
spect to ER binding of Rab3). Similar cross-binding was previ-
ously reported with respect to binding of Rab7, Rab9, and
Rab1B to endosomes where binding of all three Rab proteins
was comparable although the levels of the endogenous proteins
were not determined in that study (17).We assume that binding
as observed by our in vitro assay includes a nonspecific com-
ponent of Rab binding to any membrane. Lack of specificity was
much more pronounced when proteoliposomes reconstituted
from synaptic vesicle detergent extracts or phospholipid vesi-
cles were used as acceptor membranes.3 The enhanced nonspe-
cific component prevented the use of a detergent-based recon-
stitution approach for the purification of the receptor
protein(s).
Our data shed some new light on the initial phase of Rab
binding to membranes. The rate and the extent of Rab3A
binding is not influenced by the presence of either GDP or
GTPgS. As found for other Rab proteins, nucleotide exchange
does occur after binding but it has no effect on the binding
reaction. Furthermore, addition of cytosol had no influence on
the binding reaction, suggesting that all components required
for binding are present on the surface of synaptic vesicles.
Interestingly, we were unable to detect membrane-bound
GDI even at short incubation times. Clearly, we cannot exclude
that GDI binds but then dissociates during our centrifugation/
washing procedure. Furthermore, a recent study has suggested
that GDI may be associated with membranes in vivo, even
when not bound to a Rab protein, resulting in the proposal that
an additional, hitherto unknown Rab recycling factor is respon-
sible for directing GDI to newly formed Rab-GDP species (48).
Furthermore, a specific GDI dissociation factor has been de-
scribed that specifically displaces GDI from Rab9 and that may
be responsible for the initial step in the binding reaction (18).
The finding that GDP-Rab3A persists on the membrane after
GDI dissociation prompted us to investigate whether binding is
reversible before nucleotide exchange. Excess GDI inhibits
binding, in good agreement with similar observations on the
binding of endosomal Rab proteins (17). Interestingly, however,
bound Rab3A can be subsequently dissociated by GDI as long
as no nucleotide exchange occurs. Thus, at least in our in vitro
3 J. H. Chou and R. Jahn, unpublished observations.
FIG. 9. Binding of Rab3A is saturable and is not competed for
by Rab1B. A, competition of myc-Rab3A binding to LP2 with increas-
ing amounts of Rab1B under standard assay conditions. In the presence
of a 10-fold excess of Rab1BzGDI complex, binding of Rab3A was only
slightly reduced. B, saturation analysis of myc-Rab3A binding using
increasing amounts of myc-Rab3AzGDI complex under standard assay
conditions. Immunoblots were quantitated by densitometry and cali-
brated with a standard curve of purified Rab3A separated in parallel.
FIG. 10. The Rab3A binding site on synaptic vesicles is sensi-
tive to proteases. Synaptic vesicles (LP2) were pretreated with tryp-
sin, bromelain, and elastase (see “Experimental Procedures” for details)
and then analyzed for the binding of myc-Rab3A using standard assay
conditions. Top, membrane fractions containing bound myc-Rab3A. As
a control for proteolysis, the degradation of synaptotagmin was moni-
tored. Cleavage resulted in the generation of a 24-kDa fragment corre-
sponding to the intravesicular domain of the protein, which is protected
from protease attack (see, e.g., Ref. 50 for details). Furthermore, the
fate of endogenous Rab3A was monitored in parallel. Treatment with
all three proteases greatly reduced binding of Rab3A to vesicle mem-
branes with bromelain being most effective. Bottom panel, analysis of
the supernatant fractions recovered after centrifugation at the end of
the binding assays. No change was observed, demonstrating that no
residual protease activity was present during the incubation, which
may have resulted in a breakdown of the complex.
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system, the initial phase of membrane recruitment involves an
equilibrium between binding and dissociation. The efficiency of
recruitment would be determined by the concentration of free
GDI as much as that of GDIzRab complexes and by the rate of
nucleotide exchange. Indeed, excess GDI was shown to inhibit
in vitro transport reactions although it is noteworthy that
overexpression of GDI in intact cells appears to be less effective
(see Ref. 48 for a more detailed discussion and for references of
the older literature).
The fact that membrane-bound, GDI-sensitive GDP-Rab is
an intermediate of the re-binding reaction raises the question
how (and if) newly bound GDP-Rab proteins are distinguished
from GDP-Rab proteins that have just done their job in hydro-
lyzing GTP as a result of an interaction with GTPase-activat-
ing protein. Clearly, it is possible that nucleotide exchange is
more tightly coupled to binding in an intact systems than in our
in vitro experiments. However, since GDI appears to be able to
operate on both GDP-Rab3A pools, differentiation between
them may be due to other factors such as the above mentioned
GDI dissociation factors or Rab recycling factors. Interestingly,
several lines of evidence suggest that, although GDI is an
essential gene product, GDI-mediated dissociation may not be
a mandatory under all circumstances (see, e.g., Ref. 49). Thus it
is conceivable that membrane-bound GDP-Rab, generated by
hydrolysis from GTP-Rab, is directly re-converted into the GTP
form by guanine nucleotide exchange factor without interme-
diate involvement of GDI.
Binding of Rab3A is saturable, supporting that binding is
dependent on a Rab3A receptor on the vesicle surface. The
nature of the binding site remains to be established. Protease
pretreatment of vesicles greatly reduced binding, in agreement
with earlier reports on the binding of Rab4 (15). For Rab3A,
bromelain was most effective, but in contrast to similar exper-
iments with Rab4 (15) we were unable to reconstitute binding
by re-addition of the protease supernatant.3
In summary, our data demonstrate that synaptic vesicles
possess a specific binding mechanism for Rab3A whose prop-
erties resemble those previously characterized for endosomal
Rab proteins. They lend further support to a rebinding path-
way that proceeds in distinct steps (1). In the first step,
GDIzRab complexes bind to the target membrane. Second, GDI
is released, probably involving a specific GDI dissociation fac-
tor (18), although this step could not be resolved from the first
step in the present study. After GDI dissociation, GDP-Rab
remains bound to the membrane and subsequently undergoes
nucleotide exchange, resulting in active GTP-Rab, which does
not interact with GDI. In turn, GTP-Rab recruits appropriate
downstream effectors, which are required for its biological
activity.
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